Sagimet Biosciences Tops Q2 EPS Forecast

Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biotechnology developer focused on fatty acid synthase (FASN) inhibitors, delivered its second-quarter results on August 13, 2025. The most important news was the successful Phase 3 acne results from partner Ascletis in China, highlighting meaningful progress for its lead drug denifanstat. The company reported a net loss per share of $0.32, which was better than the consensus estimate of a $0.51 per share loss. Sagimet remains pre-revenue, so no revenue was recorded as expected. Overall, the quarter brought notable clinical successes and continued pipeline investment, but operating losses and elevated cash burn persisted. Source: Analyst estimates for the quarter provided by FactSet. Sagimet Biosciences is a U.S.-based biotechnology company developing a new class of small molecule drugs, specifically targeting fatty acid synthase (FASN). This enzyme is involved in lipid metabolism, which is linked to conditions like metabolic dysfunction-associated steatohepatitis (MASH—formerly non-alcoholic steatohepatitis), acne, and potentially some cancers. Its lead asset is denifanstat, which has advanced through mid- and late-stage clinical testing in multiple disease areas.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool